JOHNSON & JOHNSON NEW BRUNSWICK, N.J., Jan. 20, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. International sales decreased 6.7%, reflecting operational growth of 1.2% and a negative currency impact of 7.9%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 6.7%, domestic sales increased 10.7% and international sales increased 3.6%.*
Worldwide sales for the full-year 2014 were $74.3 billion, an increase of 4.2% versus 2013. Operational results increased 6.1% and the negative impact of currency was 1.9%. Domestic sales increased 9.0%. International sales increased 0.4%, reflecting operational growth of 3.7% and a negative currency impact of 3.3%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 8.0%, domestic sales increased 11.6% and international sales increased 5.1%.*
Net earnings and diluted earnings per share for the fourth quarter of 2014 were $2.5 billion and $0.89, respectively. Fourth-quarter 2014 net earnings included a charge for after-tax special items of approximately $1.1 billion, primarily related to an increase in the litigation accrual, integration costs related to the acquisition of Synthes, Inc., and an in-process research and development charge. Fourth-quarter 2013 net earnings included a net charge for after-tax special items of $42 million as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the current quarter were $3.6 billion and diluted earnings per share were $1.27, representing increases of 1.4% and 2.4%, respectively, as compared to the same period in 2013.*
Net earnings and diluted earnings per share for the full-year 2014 were $16.3 billion and $5.70, respectively. Full-year net earnings included a net charge for after-tax special items of $0.8 billion in 2014 and $2.0 billion in 2013 as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items in both periods, net earnings for the full-year of 2014 were $17.1 billion and diluted earnings per share were $5.97, representing increases of 7.7% and 8.2%, respectively, as compared with the full year of 2013.*
"2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our Pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our Medical Devices business and are continuing our market leadership with iconic brands in our Consumer business," said Alex Gorsky, Chairman and Chief Executive Officer. "I am proud of our exceptional Johnson & Johnson colleagues who make our success possible with their commitment to advancing health and well-being for patients and consumers around the world."
The Company announced adjusted earnings guidance for full-year 2015 of $6.12 to $6.27 per share. Beginning in 2015, adjusted earnings excludes after-tax intangible amortization expense in addition to special items. After-tax intangible amortization expense for 2014 was approximately $0.42 per share and for 2015 is anticipated to be approximately $0.32 per share.
Worldwide Consumer sales of $14.5 billion for the full-year 2014 represented a decrease of 1.4% versus the prior year, consisting of an operational increase of 1.0% and a negative impact from currency of 2.4%. Domestic sales decreased 1.3%; international sales decreased 1.4%, which reflected an operational increase of 2.3% and a negative currency impact of 3.7%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 2.8%, domestic sales increased 3.1% and international sales increased 2.6%.*
Positive contributors to operational results were sales of TYLENOL(®) and MOTRIN(®) analgesics and ZYRTEC(®) allergy over-the-counter products; AVEENO(®) and NEUTROGENA(®) skin care products; and LISTERINE(®) oral care products.
Worldwide Pharmaceutical sales of $32.3 billion for the full-year 2014 represented an increase of 14.9% versus the prior year with operational growth of 16.5% and a negative impact from currency of 1.6%. Domestic sales increased 25.0%; international sales increased 5.0%, which reflected an operational increase of 8.3% and a negative currency impact of 3.3%.
The strong sales results were driven by new products and the strength of our core products. New products include OLYSIO(®)/SOVRIAD(®) (simeprevir), for combination treatment of chronic hepatitis C in adult patients; XARELTO(®) (rivaroxaban), an oral anticoagulant; ZYTIGA(®) (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA(®) (canagliflozin), for the treatment of adults with type 2 diabetes; and IMBRUVICA(®) (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers.
Additional contributors to operational sales growth were STELARA(®) (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; INVEGA(®) SUSTENNA(®)/XEPLION(®) (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; SIMPONI(®)/SIMPONI ARIA(®) (golimumab) and REMICADE(®) (infliximab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases.
During the quarter, the U.S. Food and Drug Administration (FDA) granted approval for the supplemental New Drug Applications (sNDAs) for INVEGA(®) SUSTENNA(® )(paliperidone palmitate) to treat schizoaffective disorder as either monotherapy or adjunctive therapy. The European Commission approved IMBRUVICA(®) (ibrutinib) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma and adult patients with chronic lymphocytic leukemia who have received at least one prior therapy, or in first-line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. The European Commission also approved REZOLSTA(®) (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 infection in adults aged 18 years or older. In addition, VELCADE(®) (bortezomib) received a positive opinion from the European Committee for Medicinal Products for use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
Two New Drug Applications (NDAs) were submitted to the FDA for regulatory approval during the quarter. These included an NDA for three-month atypical antipsychotic paliperidone palmitate as a treatment for schizophrenia in adults as well as an NDA for YONDELIS(®) (trabectedin) for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline. Also, a supplemental NDA was submitted to the FDA and a Type II variation application was submitted to the European Medicines Agency (EMA) for an additional indication of IMBRUVICA(®) (ibrutinib) for the treatment of patients with Waldenstrom's macroglobulinemia, a rare type of B-cell lymphoma.
In addition, the acquisition of Alios BioPharma, Inc., a privately-held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, was completed. In January, a definitive agreement was announced to divest the U.S. license rights to NUCYNTA(®) (tapentadol), NUCYNTA(®) ER (tapentadol extended-release tablets), and NUCYNTA(®) (tapentadol) oral solution for approximately $1.05 billion. The transaction is expected to close in the second quarter, subject to customary closing conditions and completion of financing.
Worldwide Medical Devices sales of $27.5 billion for the full-year 2014 represented a decrease of 3.4% versus the prior year consisting of an operational decrease of 1.6% and a negative currency impact of 1.8%. Domestic sales decreased 4.3%; international sales decreased 2.7%, which reflected an operational increase of 0.5% and a negative currency impact of 3.2%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.6%, domestic sales decreased 0.6% and international sales increased 3.5%.* The divestiture of the Ortho-Clinical Diagnostics business was completed in June.
Primary contributors to operational growth were our broad portfolio of Orthopaedic products; Biosense Webster's electrophysiology products in the Cardiovascular Care business; and biosurgicals and international sales of energy products in the Specialty Surgery business.
During the quarter, the FDA approved the Animas(®) Vibe(TM) insulin pump and Continuous Glucose Monitoring system for the management of insulin-requiring diabetes in adults ages 18 and older.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,500 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
* Operational sales growth excluding the net impact of acquisitions and divestitures as well as net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company's website at www.investor.jnj.com.
Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found on the Company's website at www.investor.jnj.com.
NOTE TO INVESTORS
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new and existing products; impact of business combinations and divestitures; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; the impact of patent expirations; significant adverse litigation or government action, including related to product liability claims; changes to laws and regulations, including domestic and foreign health care reforms; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; financial instability of international economies and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited; Dollars in Millions) FOURTH QUARTER TWELVE MONTHS
------------------------------- -------------- -------------
Percent Change Percent Change
-------------- --------------
2014 2013 Total Operations Currency 2014 2013 Total Operations Currency
---- ---- ----- ---------- -------- ---- ---- ----- ---------- --------
Sales to customers by
segment of business
Consumer
U.S. $1,294 1,263 2.5% 2.5 - $5,096 5,162 (1.3)% (1.3) -
International 2,312 2,490 (7.1) 0.1 (7.2) 9,400 9,535 (1.4) 2.3 (3.7)
3,606 3,753 (3.9) 0.9 (4.8) 14,496 14,697 (1.4) 1.0 (2.4)
----- ----- ---- --- ---- ------ ------ ---- --- ----
Pharmaceutical
U.S. 4,356 3,551 22.7 22.7 - 17,432 13,948 25.0 25.0 -
International 3,643 3,745 (2.7) 5.8 (8.5) 14,881 14,177 5.0 8.3 (3.3)
7,999 7,296 9.6 13.9 (4.3) 32,313 28,125 14.9 16.5 (1.6)
----- ----- --- ---- ---- ------ ------ ---- ---- ----
Medical Devices
U.S. 2,954 3,200 (7.7) (7.7) - 12,254 12,800 (4.3) (4.3) -
International 3,695 4,106 (10.0) (2.3) (7.7) 15,268 15,690 (2.7) 0.5 (3.2)
6,649 7,306 (9.0) (4.7) (4.3) 27,522 28,490 (3.4) (1.6) (1.8)
----- ----- ---- ---- ---- ------ ------ ---- ---- ----
U.S. 8,604 8,014 7.4 7.4 - 34,782 31,910 9.0 9.0 -
International 9,650 10,341 (6.7) 1.2 (7.9) 39,549 39,402 0.4 3.7 (3.3)
Worldwide $18,254 18,355 (0.6)% 3.9 (4.5) $74,331 71,312 4.2% 6.1 (1.9)
--------- ------- ------ ----- --- ---- ------- ------ --- --- ----
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited; Dollars in Millions) FOURTH QUARTER TWELVE MONTHS
------------------------------- -------------- -------------
Percent Change Percent Change
2014 2013 Total Operations Currency 2014 2013 Total Operations Currency
---- ---- ----- ---------- -------- ---- ---- ----- ---------- --------
Sales to customers by
geographic area
U.S. $8,604 8,014 7.4% 7.4 - $34,782 31,910 9.0% 9.0 -
---- ------ ----- --- --- --- ------- ------ --- --- ---
Europe 4,560 4,968 (8.2) 0.6 (8.8) 18,947 18,599 1.9 2.6 (0.7)
Western Hemisphere excluding U.S. 1,782 1,891 (5.8) 3.9 (9.7) 7,160 7,421 (3.5) 5.2 (8.7)
Asia-Pacific, Africa 3,308 3,482 (5.0) 0.6 (5.6) 13,442 13,382 0.4 4.4 (4.0)
International 9,650 10,341 (6.7) 1.2 (7.9) 39,549 39,402 0.4 3.7 (3.3)
------------- ----- ------ ---- --- ---- ------ ------ --- --- ----
Worldwide $18,254 18,355 (0.6)% 3.9 (4.5) $74,331 71,312 4.2% 6.1 (1.9)
--------- ------- ------ ----- --- ---- ------- ------ --- --- ----
Johnson & Johnson and Subsidiaries
----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures) FOURTH QUARTER
------------------------------------------------ --------------
2014 2013 Percent
---- ----
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers $18,254 100.0 $18,355 100.0 (0.6)
------------------ ------- ----- ------- ----- ----
Cost of products sold 5,853 32.1 5,955 32.5 (1.7)
Selling, marketing and administrative expenses 5,822 31.9 5,917 32.2 (1.6)
Research and development expense 2,635 14.4 2,411 13.1 9.3
In-process research and development 156 0.8 338 1.9
Interest (income) expense, net 122 0.7 116 0.6
Other (income) expense, net 963 5.3 868 4.7
--------------------------- --- --- --- ---
Earnings before provision for taxes on income 2,703 14.8 2,750 15.0 (1.7)
Provision for/(Benefit from) taxes on income 182 1.0 (769) (4.2)
Net earnings $2,521 13.8 $3,519 19.2 (28.4)
------------ ------ ---- ------ ---- -----
Net earnings per share (Diluted) $0.89 $1.23 (27.6)
Average shares outstanding (Diluted) 2,845.3 2,872.0
Effective tax rate 6.7% (28.0)%
Adjusted earnings before provision for taxes and net earnings(1)
Earnings before provision for taxes on income $3,925 21.5 $3,909 21.3 0.4
Net earnings $3,612 19.8 $3,561 19.4 1.4
Net earnings per share (Diluted) $1.27 $1.24 2.4
Effective tax rate 8.0% 8.9%
------------------ --- ---
(1)See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures) TWELVE MONTHS
------------------------------------------------ -------------
2014 2013 Percent
---- ----
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers $74,331 100.0 $71,312 100.0 4.2
------------------ ------- ----- ------- ----- ---
Cost of products sold 22,746 30.6 22,342 31.3 1.8
Selling, marketing and administrative expenses 21,954 29.5 21,830 30.6 0.6
Research and development expense 8,494 11.4 8,183 11.5 3.8
In-process research and development 178 0.3 580 0.8
Interest (income) expense, net 466 0.6 408 0.6
Other (income) expense, net (70) (0.1) 2,498 3.5
--------------------------- --- ---- ----- ---
Earnings before provision for taxes on income 20,563 27.7 15,471 21.7 32.9
Provision for taxes on income 4,240 5.7 1,640 2.3
Net earnings $16,323 22.0 $13,831 19.4 18.0
------------ ------- ---- ------- ---- ----
Net earnings per share (Diluted) $5.70 $4.81 18.5
Average shares outstanding (Diluted) 2,863.9 2,877.0
Effective tax rate 20.6% 10.6%
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income $21,195 28.5 $19,169 26.9 10.6
Net earnings $17,105 23.0 $15,876 22.3 7.7
Net earnings per share (Diluted) $5.97 $5.52 8.2
Effective tax rate 19.3% 17.2%
------------------ ---- ----
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Fourth Quarter % Incr. / Twelve Months % Incr. /
-------------- -------------
(Dollars in Millions Except Per Share Data) 2014 2013 (Decr.) 2014 2013 (Decr.)
------------------------------------------ ---- ---- ------ ---- ---- ------
Earnings before provision for taxes on income - as reported $2,703 2,750 (1.7)% $20,563 15,471 32.9%
Ortho-Clinical Diagnostics divestiture net (gain)/expense 49 - (1,899) -
Litigation expenses 692 506 1,253 2,282
Synthes integration/transaction costs 325 181 754 683
Additional year of Branded Prescription Drug Fee - - 220 -
In-process research and development 156 338 178 580
DePuy ASRTMHip program - 134 126 251
Other - - - (98)
Earnings before provision for taxes on income - as adjusted $3,925 3,909 0.4% $21,195 19,169 10.6%
------ ----- --- ------- ------ ----
Net Earnings - as reported $2,521 3,519 (28.4)% $16,323 13,831 18.0%
Ortho-Clinical Diagnostics divestiture net (gain)/expense 87 - (1,062) -
Litigation expenses 652 227 1,225 (1) 1,646
Synthes integration/transaction costs 237 110 555 483
Additional year of Branded Prescription Drug Fee - - 220 -
In-process research and development 115 294 131 462
DePuy ASRTMHip program - 118 111 240
Tax benefit associated with Conor Medsystems - - (398) -
Scios tax benefit - (707) - (707)
Other - - - (79)
Net Earnings - as adjusted $3,612 3,561 1.4% $17,105 15,876 7.7%
------ ----- --- ------- ------ ---
Diluted Net Earnings per share - as reported $0.89 1.23 (27.6)% $5.70 4.81 18.5%
Ortho-Clinical Diagnostics divestiture net (gain)/expense 0.03 - (0.37) -
Litigation expenses 0.23 0.08 0.43 0.57
Synthes integration/transaction costs 0.08 0.04 0.19 0.17
Additional year of Branded Prescription Drug Fee - - 0.08 -
In-process research and development 0.04 0.10 0.04 0.16
DePuy ASRTMHip program - 0.04 0.04 0.08
Tax benefit associated with Conor Medsystems - - (0.14) -
Scios Tax Benefit - (0.25) - (0.25)
Other - - - (0.02)
Diluted Net Earnings per share - as adjusted $1.27 1.24 2.4% $5.97 5.52 8.2%
----- ---- --- ----- ---- ---
(1) Includes adjustment to deferred tax asset related to deductibility by tax jurisdiction
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions and Divestitures
----------------------------------------------------------------
FOURTH QUARTER 2014 ACTUAL vs. 2013 ACTUAL
Segments
--------
Operational % (1)
----------------
Consumer Pharmaceutical Medical Devices Total
-------- -------------- --------------- -----
WW As Reported: 0.9% 13.9% (4.7)% 3.9%
U.S. 2.5% 22.7% (7.7)% 7.4%
International 0.1% 5.8% (2.3)% 1.2%
Women's Health
Sanitary Protection 0.5 0.1
U.S. 1.4 0.2
International 0.1 0.0
Women's Health
K-Y (R) 0.5 0.2
U.S. 1.0 0.2
International 0.3 0.1
Diagnostics
Ortho-Clinical Diagnostics 6.2 2.5
U.S. 6.7 2.9
International 5.8 2.3
All Other Acquisitions and Divestitures 0.2 0.0
U.S. 0.0 0.0
International 0.2 0.0
WW Ops excluding Acquisitions and Divestitures 2.1% 13.9% 1.5% 6.7%
U.S. 4.9% 22.7% (1.0)% 10.7%
International 0.7% 5.8% 3.5% 3.6%
(1)Operational growth excludes the effect of translational currency
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions and Divestitures
----------------------------------------------------------------
TWELVE MONTHS 2014 ACTUAL vs. 2013 ACTUAL
Segments
--------
Operational % (1)
----------------
Consumer Pharmaceutical Medical Devices Total
-------- -------------- --------------- -----
WW As Reported: 1.0% 16.5% (1.6)% 6.1%
U.S. (1.3)% 25.0% (4.3)% 9.0%
International 2.3% 8.3% 0.5% 3.7%
Women's Health
Sanitary Protection 1.4 0.3
U.S. 3.8 0.6
International 0.1 0.0
Women's Health
K-Y (R) 0.3 0.1
U.S. 0.6 0.1
International 0.1 0.0
Diagnostics
Ortho-Clinical Diagnostics 3.2 1.4
U.S. 3.7 1.8
International 3.0 1.2
All Other Acquisitions and Divestitures 0.1 0.1 0.1
U.S. 0.0 0.1 0.1
International 0.1 0.1 0.2
WW Ops excluding Acquisitions and Divestitures 2.8% 16.6% 1.6% 8.0%
U.S. 3.1% 25.1% (0.6)% 11.6%
International 2.6% 8.4% 3.5% 5.1%
(1)Operational growth excludes the effect of translational currency
REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------
FOURTH QUARTER TWELVE MONTHS
-------------- -------------
% Change % Change
-------- --------
2014 2013 Reported Operational (1) Currency 2014 2013 Reported Operational (1) Currency
---- ---- -------- -------------- -------- ---- ---- -------- -------------- --------
CONSUMER SEGMENT (2)
-------------------
BABY CARE
---------
US $96 105 -8.6% -8.6% - $407 413 -1.5% -1.5% -
Intl 428 480 -10.8% -4.8% -6.0% 1,832 1,882 -2.7% 1.8% -4.5%
--- --- ----- -----
WW 524 585 -10.4% -5.5% -4.9% 2,239 2,295 -2.4% 1.3% -3.7%
ORAL CARE
---------
US 150 153 -2.0% -2.0% - 600 602 -0.3% -0.3% -
Intl 264 265 -0.4% 6.1% -6.5% 1,047 1,020 2.6% 5.9% -3.3%
--- --- ----- -----
WW 414 418 -1.0% 3.1% -4.1% 1,647 1,622 1.5% 3.6% -2.1%
OTC
---
US 362 332 9.0% 9.0% - 1,357 1,286 5.5% 5.5% -
Intl 711 747 -4.8% 3.6% -8.4% 2,749 2,742 0.3% 3.7% -3.4%
--- --- ----- -----
WW 1,073 1,079 -0.6% 5.2% -5.8% 4,106 4,028 1.9% 4.2% -2.3%
SKIN CARE
---------
US 471 432 9.0% 9.0% - 1,834 1,752 4.7% 4.7% -
Intl 485 538 -9.9% -3.7% -6.2% 1,924 1,952 -1.4% 1.2% -2.6%
--- --- ----- -----
WW 956 970 -1.4% 2.0% -3.4% 3,758 3,704 1.5% 2.9% -1.4%
WOMEN'S HEALTH
--------------
US 7 38 -81.6% -81.6% - 50 280 -82.1% -82.1% -
Intl 301 310 -2.9% 6.0% -8.9% 1,252 1,288 -2.8% 2.6% -5.4%
--- --- ----- -----
WW 308 348 -11.5% -3.6% -7.9% 1,302 1,568 -17.0% -12.6% -4.4%
WOUND CARE/OTHER
----------------
US 208 203 2.5% 2.5% - 848 829 2.3% 2.3% -
Intl 123 150 -18.0% -11.6% -6.4% 596 651 -8.4% -6.3% -2.1%
--- --- --- ---
WW 331 353 -6.2% -3.5% -2.7% 1,444 1,480 -2.4% -1.5% -0.9%
TOTAL CONSUMER
--------------
US 1,294 1,263 2.5% 2.5% - 5,096 5,162 -1.3% -1.3% -
Intl 2,312 2,490 -7.1% 0.1% -7.2% 9,400 9,535 -1.4% 2.3% -3.7%
----- ----- ----- -----
WW $3,606 3,753 -3.9% 0.9% -4.8% $14,496 14,697 -1.4% 1.0% -2.4%
====== ===== ======= ======
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------
FOURTH QUARTER TWELVE MONTHS
-------------- -------------
% Change % Change
-------- --------
2014 2013 Reported Operational (1) Currency 2014 2013 Reported Operational (1) Currency
---- ---- -------- -------------- -------- ---- ---- -------- -------------- --------
PHARMACEUTICAL SEGMENT (2) (3)
-----------------------------
IMMUNOLOGY
----------
US $1,816 1,726 5.2% 5.2% - $7,111 6,591 7.9% 7.9% -
Intl 762 676 12.7% 22.2% -9.5% 3,082 2,599 18.6% 23.3% -4.7%
--- --- ----- -----
WW 2,578 2,402 7.3% 10.0% -2.7% 10,193 9,190 10.9% 12.2% -1.3%
REMICADE
--------
US $1,052 982 7.1% 7.1% - 4,155 3,891 6.8% 6.8% -
US Exports (4) 244 367 -33.5% -33.5% - 1,078 1,339 -19.5% -19.5% -
Intl 376 363 3.6% 12.6% -9.0% 1,635 1,443 13.3% 19.0% -5.7%
--- --- ----- -----
WW 1,672 1,712 -2.3% -0.4% -1.9% 6,868 6,673 2.9% 4.1% -1.2%
SIMPONI/SIMPONI ARIA
--------------------
US 164 112 46.4% 46.4% - 544 404 34.7% 34.7% -
Intl 182 142 28.2% 39.0% -10.8% 643 528 21.8% 26.4% -4.6%
--- --- --- ---
WW 346 254 36.2% 42.2% -6.0% 1,187 932 27.4% 30.0% -2.6%
STELARA
-------
US 356 265 34.3% 34.3% - 1,334 957 39.4% 39.4% -
Intl 189 152 24.3% 34.3% -10.0% 738 547 34.9% 37.3% -2.4%
--- --- --- ---
WW 545 417 30.7% 34.4% -3.7% 2,072 1,504 37.8% 38.7% -0.9%
OTHER IMMUNOLOGY
----------------
US - - - - - - - - - -
Intl 15 19 -21.1% -15.9% -5.2% 66 81 -18.5% -14.3% -4.2%
--- --- --- ---
WW 15 19 -21.1% -15.9% -5.2% 66 81 -18.5% -14.3% -4.2%
INFECTIOUS DISEASES
-------------------
US 564 302 86.8% 86.8% - 3,112 1,077 * * -
Intl 512 642 -20.2% -12.1% -8.1% 2,487 2,473 0.6% 2.5% -1.9%
--- --- ----- -----
WW 1,076 944 14.0% 19.5% -5.5% 5,599 3,550 57.7% 58.6% -0.9%
EDURANT
-------
US 6 5 20.0% 20.0% - 24 15 60.0% 60.0% -
Intl 84 68 23.5% 33.8% -10.3% 341 221 54.3% 54.3% 0.0%
--- --- --- ---
WW 90 73 23.3% 32.9% -9.6% 365 236 54.7% 54.7% 0.0%
INCIVO
------
US - - - - - - - - - -
Intl 5 107 -95.3% -90.7% -4.6% 226 517 -56.3% -55.0% -1.3%
--- --- --- ---
WW 5 107 -95.3% -90.7% -4.6% 226 517 -56.3% -55.0% -1.3%
OLYSIO/SOVRIAD
--------------
US 256 13 * * - 1,943 13 * * -
Intl 65 10 * * -12.5% 359 10 * * -2.3%
--- --- --- ---
WW 321 23 * * -2.5% 2,302 23 * * -0.4%
PREZISTA
--------
US 243 229 6.1% 6.1% - 930 807 15.2% 15.2% -
Intl 205 232 -11.6% -3.5% -8.1% 901 866 4.0% 5.9% -1.9%
--- --- --- ---
WW 448 461 -2.8% 1.3% -4.1% 1,831 1,673 9.4% 10.4% -1.0%
OTHER INFECTIOUS DISEASES
-------------------------
US 59 55 7.3% 7.3% - 215 242 -11.2% -11.2% -
Intl 153 225 -32.0% -26.1% -5.9% 660 859 -23.2% -21.2% -2.0%
--- --- --- ---
WW 212 280 -24.3% -19.6% -4.7% 875 1,101 -20.5% -18.9% -1.6%
--- --- ----- ----- ---- --- ----- ----- ----- ----
REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------
FOURTH QUARTER TWELVE MONTHS
-------------- -------------
% Change % Change
-------- --------
2014 2013 Reported Operational (1) Currency 2014 2013 Reported Operational (1) Currency
---- ---- -------- -------------- -------- ---- ---- -------- -------------- --------
NEUROSCIENCE
------------
US 645 611 5.6% 5.6% - 2,452 2,584 -5.1% -5.1% -
Intl 1,006 1,040 -3.3% 5.1% -8.4% 4,035 4,083 -1.2% 2.2% -3.4%
----- ----- ----- -----
WW 1,651 1,651 0.0% 5.3% -5.3% 6,487 6,667 -2.7% -0.6% -2.1%
CONCERTA/METHYLPHENIDATE
------------------------
US 55 46 19.6% 19.6% - 152 308 -50.6% -50.6% -
Intl 114 123 -7.3% 0.5% -7.8% 447 474 -5.7% -1.6% -4.1%
--- --- --- ---
WW 169 169 0.0% 5.7% -5.7% 599 782 -23.4% -20.9% -2.5%
INVEGA
------
US 96 87 10.3% 10.3% - 360 316 13.9% 13.9% -
Intl 65 67 -3.0% 7.0% -10.0% 280 267 4.9% 8.7% -3.8%
--- --- --- ---
WW 161 154 4.5% 8.9% -4.4% 640 583 9.8% 11.5% -1.7%
INVEGA SUSTENNA/ XEPLION
------------------------
US 226 188 20.2% 20.2% - 825 690 19.6% 19.6% -
Intl 192 162 18.5% 27.8% -9.3% 763 558 36.7% 39.1% -2.4%
--- --- --- ---
WW 418 350 19.4% 23.7% -4.3% 1,588 1,248 27.2% 28.3% -1.1%
RISPERDAL CONSTA
----------------
US 104 113 -8.0% -8.0% - 427 440 -3.0% -3.0% -
Intl 190 208 -8.7% -0.5% -8.2% 763 878 -13.1% -10.9% -2.2%
--- --- --- ---
WW 294 321 -8.4% -3.1% -5.3% 1,190 1,318 -9.7% -8.2% -1.5%
OTHER NEUROSCIENCE
------------------
US 164 177 -7.3% -7.3% - 688 830 -17.1% -17.1% -
Intl 445 480 -7.3% 0.8% -8.1% 1,782 1,906 -6.5% -2.4% -4.1%
--- --- ----- -----
WW 609 657 -7.3% -1.4% -5.9% 2,470 2,736 -9.7% -6.9% -2.8%
ONCOLOGY
--------
US 334 216 54.6% 54.6% - 1,157 848 36.4% 36.4% -
Intl 878 897 -2.1% 6.7% -8.8% 3,300 2,925 12.8% 16.0% -3.2%
--- --- ----- -----
WW 1,212 1,113 8.9% 16.0% -7.1% 4,457 3,773 18.1% 20.6% -2.5%
VELCADE
-------
US - - - - - - - - - -
Intl 418 524 -20.2% -12.1% -8.1% 1,618 1,660 -2.5% 1.1% -3.6%
--- --- ----- -----
WW 418 524 -20.2% -12.1% -8.1% 1,618 1,660 -2.5% 1.1% -3.6%
ZYTIGA
------
US 255 211 20.9% 20.9% - 971 750 29.5% 29.5% -
Intl 340 284 19.7% 29.9% -10.2% 1,266 948 33.5% 36.1% -2.6%
--- --- ----- ---
WW 595 495 20.2% 26.0% -5.8% 2,237 1,698 31.7% 33.1% -1.4%
OTHER ONCOLOGY
--------------
US 79 5 * * - 186 98 89.8% 89.8% -
Intl 120 89 34.8% 43.9% -9.1% 416 317 31.2% 34.2% -3.0%
--- --- --- ---
WW 199 94 * * -8.6% 602 415 45.1% 47.4% -2.3%
--- --- --- --- ---- --- --- ---- ---- ----
REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------
FOURTH QUARTER TWELVE MONTHS
-------------- -------------
% Change % Change
-------- --------
2014 2013 Reported Operational (1) Currency 2014 2013 Reported Operational (1) Currency
---- ---- -------- -------------- -------- ---- ---- -------- -------------- --------
TOTAL OTHER
-----------
US 997 696 43.2% 43.2% - 3,600 2,848 26.4% 26.4% -
Intl 485 490 -1.0% 6.0% -7.0% 1,977 2,097 -5.7% -3.4% -2.3%
--- --- ----- -----
WW 1,482 1,186 25.0% 27.9% -2.9% 5,577 4,945 12.8% 13.8% -1.0%
PROCRIT/EPREX
-------------
US 177 168 5.4% 5.4% - 715 795 -10.1% -10.1% -
Intl 125 139 -10.1% -3.2% -6.9% 523 569 -8.1% -6.2% -1.9%
--- --- --- ---
WW 302 307 -1.6% 1.5% -3.1% 1,238 1,364 -9.2% -8.4% -0.8%
XARELTO
-------
US 428 271 57.9% 57.9% - 1,522 864 76.2% 76.2% -
Intl - - - - - - - - - -
--- --- --- ---
WW 428 271 57.9% 57.9% - 1,522 864 76.2% 76.2% -
OTHER
-----
US 392 257 52.5% 52.5% - 1,363 1,189 14.6% 14.6% -
Intl 360 351 2.6% 9.6% -7.0% 1,454 1,528 -4.8% -2.4% -2.4%
--- --- ----- -----
WW 752 608 23.7% 27.7% -4.0% 2,817 2,717 3.7% 5.0% -1.3%
TOTAL PHARMACEUTICAL
--------------------
US 4,356 3,551 22.7% 22.7% - 17,432 13,948 25.0% 25.0% -
Intl 3,643 3,745 -2.7% 5.8% -8.5% 14,881 14,177 5.0% 8.3% -3.3%
----- ----- ------ ------
WW $7,999 7,296 9.6% 13.9% -4.3% $32,313 28,125 14.9% 16.5% -1.6%
====== ===== ======= ======
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
------------------------------------
FOURTH QUARTER TWELVE MONTHS
-------------- -------------
% Change % Change
-------- --------
2014 2013 Reported Operational (1) Currency 2014 2013 Reported Operational (1) Currency
---- ---- -------- -------------- -------- ---- ---- -------- -------------- --------
MEDICAL DEVICES (2) (3) (7)
--------------------------
CARDIOVASCULAR CARE
-------------------
US $222 210 5.7% 5.7% - $862 808 6.7% 6.7% -
Intl 336 324 3.7% 12.4% -8.7% 1,346 1,269 6.1% 9.4% -3.3%
--- --- ----- -----
WW 558 534 4.5% 9.8% -5.3% 2,208 2,077 6.3% 8.3% -2.0%
DIABETES CARE
-------------
US 206 219 -5.9% -5.9% - 864 998 -13.4% -13.4% -
Intl 308 344 -10.5% -1.5% -9.0% 1,278 1,311 -2.5% 0.8% -3.3%
--- --- ----- -----
WW 514 563 -8.7% -3.2% -5.5% 2,142 2,309 -7.2% -5.3% -1.9%
DIAGNOSTICS (5)
--------------
US - 215 ** ** - 456 926 -50.8% -50.8% -
Intl 14 251 -94.4% -90.5% -3.9% 506 959 -47.2% -44.9% -2.3%
--- --- --- ---
WW 14 466 -97.0% -94.9% -2.1% 962 1,885 -49.0% -47.8% -1.2%
ORTHOPAEDICS
------------
US 1,339 1,307 2.4% 2.4% - 5,197 5,074 2.4% 2.4% -
Intl 1,102 1,149 -4.1% 3.3% -7.4% 4,478 4,435 1.0% 3.5% -2.5%
----- ----- ----- -----
WW 2,441 2,456 -0.6% 2.8% -3.4% 9,675 9,509 1.7% 2.9% -1.2%
SPECIALTY SURGERY/OTHER (6)
---------------------------
US 425 422 0.7% 0.7% - 1,679 1,664 0.9% 0.9% -
Intl 479 507 -5.5% 2.1% -7.6% 1,862 1,840 1.2% 4.9% -3.7%
--- --- ----- -----
WW 904 929 -2.7% 1.5% -4.2% 3,541 3,504 1.1% 3.0% -1.9%
SURGICAL CARE
-------------
US 567 599 -5.3% -5.3% - 2,221 2,294 -3.2% -3.2% -
Intl 1,005 1,040 -3.4% 4.0% -7.4% 3,955 3,975 -0.5% 2.6% -3.1%
----- ----- ----- -----
WW 1,572 1,639 -4.1% 0.6% -4.7% 6,176 6,269 -1.5% 0.5% -2.0%
VISION CARE
-----------
US 195 228 -14.5% -14.5% - 975 1,036 -5.9% -5.9% -
Intl 451 491 -8.1% 1.7% -9.8% 1,843 1,901 -3.1% 1.7% -4.8%
--- --- ----- -----
WW 646 719 -10.2% -3.5% -6.7% 2,818 2,937 -4.1% -1.0% -3.1%
TOTAL MEDICAL DEVICES
---------------------
US 2,954 3,200 -7.7% -7.7% - 12,254 12,800 -4.3% -4.3% -
Intl 3,695 4,106 -10.0% -2.3% -7.7% 15,268 15,690 -2.7% 0.5% -3.2%
----- ----- ------ ------
WW $6,649 7,306 -9.0% -4.7% -4.3% $27,522 28,490 -3.4% -1.6% -1.8%
====== ===== ======= ======
* Percentage greater than 100%
** Not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Prior year amounts have been reclassified to conform to current year product disclosure
(4) Reported as U.S. sales
(5) Reflects Diagnostics divestiture June 30, 2014
(6) Infection Prevention now reflected in Specialty Surgery/Other, previously reported independently
(7) Previously referred to as Medical Devices and Diagnostics
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2014-fourth-quarter-and-full-year-results-300022758.html
SOURCE Johnson & Johnson
